Boston, MAPhone: 617-724-3456
About Philip Amrein, MD
- Acute Leukemia
- Chronic leukemia
- Myeloproliferative neoplasms
Mass General Cancer Center: Hematology/Oncology BMT Program
100 Blossom Street
Boston, MA 02114
- MD, Johns Hopkins University School of Medicine
- Residency, Yale Waterbury Hospital
- Fellowship, Massachusetts General Hospital*****
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
- Medical Oncology, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- Mass General Brigham Health Plan - ACD
- Mass General Brigham Health Plan - PBO
- Medicare - ACD
- Medicare ACO - ACD
- Medicare ACO - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - New York
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Schiffer CA,...Amrein PC,..."A double-blind, placebo-controlled trial of pegylated recombinant MGDF as an adjunct to induction and consolidation therapy to patients with acute myeloid leukemia". Blood 2000;95:2530-2535.
- Moore JO,...Amrein PC,...."Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: CALGB study 9222". Blood 2005;105:3420-3427.
- Attar EC,...Amrein PC. "Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with AML". Clinical Cancer Research 2008;14:1446-1454.
- DeAngelo D,...Amrein PC,..."A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphocytic leukemia". Blood (ASH abstract #580) 2007.
- Amrein PC, et al. "Dasatinib has activity in relapsed/refractory CLL/SLL". Blood (ASH abstract #3162) 2008.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Cancer Center is among the leading U.S. cancer care providers.
#1 Research Hospital in America
Mass General is the #1 hospital in New England based on U.S. News & World Report Best Hospitals for 2022-2023.
Reviews: Comments and Ratings